Back to User profile » Dr David B Rubin
Papers published by Dr David B Rubin:
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/YCq1mqQ5Xl4/1.jpg)
Pavord ID, Chapman KR, Bafadhel M, Sciurba FC, Bradford ES, Schweiker Harris S, Mayer B, Rubin DB, Yancey SW, Paggiaro P
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1755-1770
Published Date: 16 June 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Plain language summary](assets/img/article_icons/plain-language.png)
Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness
Horne BD, Ali R, Midwinter D, Scott-Wilson C, Crim C, Miller BE, Rubin DB
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:41-51
Published Date: 7 January 2021
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Predictors of pneumonia on routine chest radiographs in patients with COPD: a post hoc analysis of two 1-year randomized controlled trials
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/NVvdKN59Ipo/1.jpg)
Rubin DB, Ahmad HA, O'Neal M, Bennett S, Lettis S, Galkin DV, Crim C
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:189-201
Published Date: 8 January 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD
Bhatt SP, Dransfield MT, Cockcroft JR, Wang-Jairaj J, Midwinter DA, Rubin DB, Scott-Wilson CA, Crim C
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:351-365
Published Date: 19 January 2017
![Noteworthy Comment: This paper is one of the very first to not only clearly confirm the finding that inhaled steroids in COPD increase the risk of pneumonia but it also describes the some possible sub groups of patients who are at increased risk. This should aid the clinician in making decisions as to when and if to start inhaled steroids. Moreover we need to not only phenotype our patients for their possible responsiveness but also for their risk of significant harm due in part to medication, in this instance pneumonia driven by inhaled steroids.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis
DiSantostefano RL, Li H, Hinds D, Galkin DV, Rubin DB
International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:457-468
Published Date: 7 May 2014